Celgosivir is a new class of antiviral medicine in clinical development for the treatment of chronic hepatitis C virus (HCV) infection. Researchers tested this new antiviral medicine and measured its potential to offer improved treatment outcomes when combined with other anti-HCV drugs.
Doctors at UPMC have begun a study using an investigational cardiac device, the VentrAssist? Left Ventricular Assist System (LVAD) to see whether it can be used safely and effectively in patients with end-stage heart failure.
By correlating images of cancerous liver tissue with gene expression patterns, a research team led by a radiologist at the University of California, San Diego (UCSD) School of Medicine has developed tools that may some day allow physicians to view a CT image of a cancer tumor and discern its genetic activity.
Researchers at the University of Minnesota and the University of Illinois at Urbana-Champaign have developed a new therapeutic that neutralizes Toxic Shock Syndrome (TSS) more effectively than other treatments.
University of Florida researchers used gene therapy to restore sight in mice with a form of hereditary blindness, a finding that has bearing on many of the most common blinding diseases.
Hepatocellular carcinoma (HCC), a cancer of cells in the liver, is on the rise in part due to the high prevalence of chronic hepatitis C infection, which increases the risk for the disease.
The University of California, San Diego Medical Center along with nine other clinical research institutions across the United States has completed the largest randomized clinical trial to date comparing two commonly performed surgical procedures to treat urinary stress incontinence.
Millions of Americans take medications for hypertension but do not achieve control of their blood pressure. Single-tablet combinations of drugs may be what it takes to get blood pressure under control, even in people with moderate hypertension, according to results from a new international study involving more than 10,700 people with high blood pressure.
A new study of intensive care unit patients who are breathing with the help of a mechanical ventilator has found that a two-step sedation and ventilator weaning protocol?called a ?wake up and breathe? strategy?helps patients come off the ventilator faster so that they can be discharged from the ICU and hospital more quickly.
Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist? (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).